Compare
Eloxx Pharmaceuticals, Inc. vs Amgen Inc vs Repligen Corp vs Biogen Inc.
| Latest fiscal year | Eloxx Pharmaceuticals, Inc. ELOX | Amgen Inc AMGN | Repligen Corp RGEN | Biogen Inc. BIIB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $0 | $36.75B | $738.26M | $9.89B |
| Revenue growth (YoY) | -100.0% | +10.0% | +16.4% | +2.2% |
| Gross margin | n/a | 67.2% (computed) | 52.3% (computed) | 75.7% (computed) |
| Operating margin | n/a | 24.7% | 7.5% | n/a |
| Net margin | n/a | 21.0% | 6.6% | 13.1% |
| Net income | -$6.00M | $7.71B | $48.89M | $1.29B |
| EPS (Diluted) | -$0.49 | $14.23 | $0.86 | $8.79 |
| Operating cash flow | -$6.33M | $9.96B | $117.42M | $2.20B |
| Free cash flow | n/a | $8.10B | $93.90M | $2.05B |
| Cash & equivalents | $4.79M | $9.13B | $566.02M | n/a |
| Total assets | $5.27M | $90.59B | $2.95B | $29.44B |
| Total liabilities | $17.18M | n/a | $843.57M | $11.18B |
| Shareholders' equity | -$11.91M | $8.66B | $2.11B | $18.26B |
| Return on year-end equity | n/a | 89.1% | 2.3% | 7.1% |
| Shares outstanding | 4.79M | 538.80M | 56.33M | 146.80M |
Revenue, most recent five fiscal years
| Fiscal year | Eloxx Pharmaceuticals, Inc. | Amgen Inc | Repligen Corp | Biogen Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2025-12-31 | $36.75B Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $9.89B Ended 2025-12-31 |
| 1 year earlier | $6.36M Ended 2024-12-31 | $33.42B Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $9.68B Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2023-12-31 | $28.19B Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $9.84B Ended 2023-12-31 |
| 3 years earlier | n/a | $26.32B Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $10.17B Ended 2022-12-31 |
| 4 years earlier | n/a | $25.98B Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $10.98B Ended 2021-12-31 |